1. Home
  2. ACRV vs SCWO Comparison

ACRV vs SCWO Comparison

Compare ACRV & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • SCWO
  • Stock Information
  • Founded
  • ACRV 2018
  • SCWO 2021
  • Country
  • ACRV United States
  • SCWO United States
  • Employees
  • ACRV N/A
  • SCWO N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • SCWO Environmental Services
  • Sector
  • ACRV Health Care
  • SCWO Utilities
  • Exchange
  • ACRV Nasdaq
  • SCWO Nasdaq
  • Market Cap
  • ACRV 41.7M
  • SCWO 35.5M
  • IPO Year
  • ACRV 2022
  • SCWO N/A
  • Fundamental
  • Price
  • ACRV $1.33
  • SCWO $0.26
  • Analyst Decision
  • ACRV Buy
  • SCWO
  • Analyst Count
  • ACRV 7
  • SCWO 0
  • Target Price
  • ACRV $17.40
  • SCWO N/A
  • AVG Volume (30 Days)
  • ACRV 213.8K
  • SCWO 1.1M
  • Earning Date
  • ACRV 08-13-2025
  • SCWO 08-12-2025
  • Dividend Yield
  • ACRV N/A
  • SCWO N/A
  • EPS Growth
  • ACRV N/A
  • SCWO N/A
  • EPS
  • ACRV N/A
  • SCWO N/A
  • Revenue
  • ACRV N/A
  • SCWO $1,231,413.00
  • Revenue This Year
  • ACRV N/A
  • SCWO $5,945.19
  • Revenue Next Year
  • ACRV $1,037.93
  • SCWO $106.82
  • P/E Ratio
  • ACRV N/A
  • SCWO N/A
  • Revenue Growth
  • ACRV N/A
  • SCWO 403.17
  • 52 Week Low
  • ACRV $1.05
  • SCWO $0.16
  • 52 Week High
  • ACRV $10.16
  • SCWO $1.99
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 51.00
  • SCWO 52.39
  • Support Level
  • ACRV $1.27
  • SCWO $0.22
  • Resistance Level
  • ACRV $1.42
  • SCWO $0.26
  • Average True Range (ATR)
  • ACRV 0.08
  • SCWO 0.02
  • MACD
  • ACRV 0.00
  • SCWO 0.00
  • Stochastic Oscillator
  • ACRV 55.32
  • SCWO 64.03

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

Share on Social Networks: